Antifungal therapy for newborn infants with invasive fungal infection

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 6, 2012, Pages

  Clerihew, Linda ^a   McGuire, William ^b  

^a NHS TAYSIDE   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE;

HUMAN; MYCOSIS; NEWBORN; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; FLUCONAZOLE; FLUCYTOSINE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84871723556     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003953.pub3     Document Type: Article

References (50)

1. Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D, et al. Fluconazole versus amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatric Infectious Disease Journal 1996;15:1107-12. [MEDLINE: 8970221 8970221 8970221]
2. Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Archives of Disease in Childhood. Fetal and Neonatal Edition 2001;84:F131-3.
3. Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. The Journal of Antimicrobial Chemotherapy 2007;59:1076-83. [PUBMED: 17468115]
4. Benjamin DK Jr, Poole C, Steibach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003;112:634-40.
5. Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117:84-92.
6. Blyth CC, Chen SC, Slavin MA, Serena C, Nguyen Q, Marriott D, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009;123:1360-8.
7. Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD006343.pub2]
8. Caudle KE, Inger AG, Butler DR, Rogers PD. Echinocandin use in the neonatal intensive care unit. The Annals of Pharmacotherapy 2012;46:108-16.
9. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011;71:11-41. [PUBMED: 21175238]
10. Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Archives of Disease in Childhood. Fetal and Neonatal Edition 2006;91:F188-92.
11. Falagas ME, Ntziora F, Betsi GI, Samonis G. Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials. International Journal of Antimicrobial Agents 2007;29:136-43. [PUBMED: 17207609]
12. Frattarelli DA, Reed MD, Giacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs 2004;64:949-68.
13. Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatric Infectious Disease Journal 2000;19:499-504.
14. Gussenhoven MJ, Haak A, Peereboom-Wynia JD, van't Wout JW. Stevens-Johnson syndrome after fluconazole. Lancet 1991;338:120.
15. Heresi GP, Gerstmann DR, Reed MD, van den Anker JN, Blumer JL, Kovanda L, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatric Infectious Disease Journal 2006;25:1110-5.
16. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
17. Hill HR, Mitchell TG, Matsen JM, Quie PG. Recovery from disseminated candidiasis in a premature neonate. Pediatrics 1974;53:748-52.
18. Huttova M, Hartmanova I, Kralinsky K, Filka J, Uher J, Kurak J, et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatric Infectious Disease Journal 1998;17:1012-5.
19. Johansen HK, Gotzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD000969]
20. Johansen HK, Gotzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD000239]
21. Jorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004707.pub2]
22. Juster-Reicher A, Leibovitz E, Linder N, Amitay M, Flidel-Rimon O, Even-Tov S, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000;28:223-6.
23. Karlowicz MG, Rowen JL, Barnes-Eley ML, Burke BL, Lawson ML, Bendel CM, et al. The role of birth weight and gestational age in distinguishing extremely low birth weight infants at high risk of developing candidemia from infants at low risk: a multicenter study. Pediatric Research 2002;51:301A.
24. Keele DJ, DeLallo VC, Lewis RE, Ernst EJ, Klepser ME. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagnostic Microbiology and Infectious Disease 2001;41:121-6.
25. King KY, Edwards MS, Word BM. Hepatitis associated with micafungin use in a preterm infant. Journal of Perinatology 2009;29:320-2.
26. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 2001;44:125-35.
27. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clinical Infectious Diseases 2006;42:938-44. [PUBMED: 16511756]
28. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27. [PUBMED: 17482982]
29. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. The Journal of Antimicrobial Chemotherapy 2006;57:705-8. [PUBMED: 16464893]
30. Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics 2002;109:34-9.
31. Manzar S, Kamat M, Pyati S. Caspofungin for refractory candidemia in neonates. Pediatric Infectious Disease Journal 2006; Vol. 25:282-3. [PUBMED: 16511405]
32. McDougall PN, Fleming PJ, Speller DC, Daish P, Speidel BD. Neonatal systemic candidiasis: a failure to respond to intravenous miconazole in two neonates. Archives of Disease in Childhood 1982;57:884-6.
33. Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. Journal of Perinatology 2005;25:770-7. [PUBMED: 16222348]
34. Neely MN, Schreiber JR. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics 2001;107:404-5.
35. Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfaro B, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatric Infectious Disease Journal 2004;23:1093-7. [PUBMED: 15626944]
36. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
37. Robinson JL, Davies HD, Barton M, O'Brien K, Simpson K, Asztalos E, et al. Characteristics and outcome of infants with candiduria in neonatal intensive care - a Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. BMC Infectious Diseases 2009;9:183. [PUBMED: 19930662]
38. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey Study Group. Pediatric Infectious Diseases Journal 2000;19:319-24.
39. Smith PB, Steinbach WJ, Cotten CM, Schell WA, Perfect JR, Walsh TJ, et al. Caspofungin for the treatment of azole resistant candidemia in a premature infant. Journal of Perinatology 2007;27:127-9. [PUBMED: 17262048]
40. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics 1996;129:63-71.
41. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91.
42. Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. The Annals of Pharmacotherapy 2009;43:1647-57. [PUBMED: 19724014]
43. Te Dorsthorst DT, Verweij PE, Meletiadis J, Bergervoet M, Punt NC, Meis JF, et al. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrobial Agents and Chemotherapy 2002;46:2982-9.
44. Tuck S. Neonatal systemic candidiasis treated with miconazole. Archives of Disease in Childhood 1980;55:903-6.
45. VandenBussche HL, Van Loo DA. A clinical review of echinocandins in pediatric patients. The Annals of Pharmacotherapy 2010;44:166-77. [PUBMED: 20009006]
46. Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al. Neonatal infections in England: the NeonIN surveillance network. Archives of Disease in Childhood Fetal and Neonatal Edition 2011;96:F9-F14. [PUBMED: 20876594]
47. Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 2000;46:86-94.
48. Weitkamp JH, Poets CF, Sievers R, Musswessels E, Groneck P, Thomas P, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998;26:11-5.
49. Yalaz M, Akisu M, Hilmioglu S, Calkavur S, Cakmak B, Kultursay N. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses 2006; Vol. 49:242-5. [PUBMED: 16681818]
50. Clerihew L, McGuire W. Systemic antifungal drugs for invasive fungal infection in preterm infants. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003953.pub2]